Suppr超能文献

药用共晶体:监管与战略层面、设计与开发

Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.

作者信息

Gadade Dipak Dilip, Pekamwar Sanjay Sudhakar

机构信息

School of Pharmacy, S.R.T.M. University, Vishnupuri, Nanded - 431606, India.

出版信息

Adv Pharm Bull. 2016 Dec;6(4):479-494. doi: 10.15171/apb.2016.062. Epub 2016 Dec 22.

Abstract

Cocrystal is a concept of the supramolecular chemistry which is gaining the extensive interest of researchers from pharmaceutical and chemical sciences and of drug regulatory agencies. The prominent reason of which is its ability to modify physicochemical properties of active pharmaceutical ingredients. During the development of the pharmaceutical product, formulators have to optimize the physicochemical properties of active pharmaceutical ingredients. Pharmaceutical cocrystals can be employed to improve vital physicochemical characteristics of a drug, including solubility, dissolution, bioavailability and stability of pharmaceutical compounds while maintaining its therapeutic activity. It is advantageous being a green synthesis approach for production of pharmaceutical compounds. The formation polymorphic forms, solvates, hydrates and salts of cocrystals during the synthesis reported in the literature which can be a potential issue in the development of pharmaceutical cocrystals. The approaches like hydrogen bonding rules, solubility parameters, screening through the CSD database or thermodynamic characteristics can be utilized for the rational design of cocrystals and selection of coformers for synthesis multi-component cocrystals. Considering the significance of pharmaceutical cocrystals pharmaceutical regulatory authorities in the United States and Europe issued guidance documents which may be helpful for pharmaceutical product registration in these regions. In this article, we deal with the design, synthesis, strategic aspects and characteristics of cocrystals along perspectives on its regulatory and intellectual property considerations.

摘要

共晶是超分子化学的一个概念,正引起制药和化学科学领域的研究人员以及药品监管机构的广泛关注。其主要原因在于它能够改变活性药物成分的物理化学性质。在药品开发过程中,配方设计师必须优化活性药物成分的物理化学性质。药物共晶可用于改善药物的重要物理化学特性,包括药物化合物的溶解度、溶出度、生物利用度和稳定性,同时保持其治疗活性。作为一种生产药物化合物的绿色合成方法,它具有优势。文献报道在合成过程中共晶会形成多晶型物、溶剂化物、水合物和盐,这在药物共晶开发中可能是一个潜在问题。诸如氢键规则、溶解度参数、通过CSD数据库筛选或热力学特性等方法可用于共晶的合理设计以及选择共形成物以合成多组分共晶。考虑到药物共晶的重要性,美国和欧洲的药品监管当局发布了指导文件,这可能有助于在这些地区进行药品注册。在本文中,我们从共晶的监管和知识产权考量的角度探讨了共晶的设计、合成、战略方面和特性。

相似文献

5
8
Characterization and Quality Control of Pharmaceutical Cocrystals.药用共晶体的表征与质量控制
Chem Pharm Bull (Tokyo). 2016 Oct 1;64(10):1421-1430. doi: 10.1248/cpb.c16-00233. Epub 2016 Jun 18.

引用本文的文献

3
Highly Soluble Dacarbazine Multicomponent Crystals Less Prone to Photodegradation.高溶解性达卡巴嗪多组分晶体不易光降解。
Mol Pharm. 2024 Jul 1;21(7):3661-3673. doi: 10.1021/acs.molpharmaceut.4c00393. Epub 2024 Jun 10.

本文引用的文献

6
Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics.药物共晶的影响:对药物药代动力学的影响。
Expert Opin Drug Metab Toxicol. 2014 Sep;10(9):1255-71. doi: 10.1517/17425255.2014.942281. Epub 2014 Aug 4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验